-
Je něco špatně v tomto záznamu ?
Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
V. Adámková, I. Mareković, J. Szabó, L. Pojnar, S. Billová, S. Horvat Herceg, A. Kuraieva, B. Możejko-Pastewka
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- antibakteriální látky farmakologie terapeutické užití MeSH
- azabicyklické sloučeniny MeSH
- ceftazidim farmakologie MeSH
- Enterobacteriaceae MeSH
- fixní kombinace léků MeSH
- kolistin * farmakologie MeSH
- lidé MeSH
- meropenem MeSH
- mikrobiální testy citlivosti MeSH
- Pseudomonas aeruginosa * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Chorvatsko MeSH
- Litva MeSH
- Lotyšsko MeSH
- Maďarsko MeSH
- Polsko MeSH
Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime-avibactam and colistin; respectively, susceptibility rates among P. aeruginosa (n = 701) were 89.2%, 92.2% and 99.9%; difficult-to-treat (DTR) isolates, 62.5%, 37.5% and 100%; multidrug-resistant (MDR) isolates, 68.3%, 72.9% and 99.5%; meropenem-resistant (MEM-R), metallo-β-lactamase-negative (MBL-negative) isolates, 72.8%, 78.6% and 100%. Among Enterobacterales (n = 1639), susceptibility to ceftazidime-avibactam, colistin and tigecycline was ≥ 97.9%; MDR Enterobacterales, 96.8%, 94.4% and 100%, respectively; DTR isolates, ≥ 76.2% to ceftazidime-avibactam and colistin; MEM-R, MBL-negative isolates, ≥ 90.0% to ceftazidime-avibactam and colistin.
Department of Clinical and Molecular Microbiology University Hospital Centre Zagreb Zagreb Croatia
Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Microbiology University Hospital Cracow Poland
Pfizer Export B 5 RO Kyiv Ukraine
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018157
- 003
- CZ-PrNML
- 005
- 20220804134606.0
- 007
- ta
- 008
- 220720s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10096-022-04452-1 $2 doi
- 035 __
- $a (PubMed)35596097
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Adámková, V $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic
- 245 10
- $a Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019 / $c V. Adámková, I. Mareković, J. Szabó, L. Pojnar, S. Billová, S. Horvat Herceg, A. Kuraieva, B. Możejko-Pastewka
- 520 9_
- $a Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime-avibactam and colistin; respectively, susceptibility rates among P. aeruginosa (n = 701) were 89.2%, 92.2% and 99.9%; difficult-to-treat (DTR) isolates, 62.5%, 37.5% and 100%; multidrug-resistant (MDR) isolates, 68.3%, 72.9% and 99.5%; meropenem-resistant (MEM-R), metallo-β-lactamase-negative (MBL-negative) isolates, 72.8%, 78.6% and 100%. Among Enterobacterales (n = 1639), susceptibility to ceftazidime-avibactam, colistin and tigecycline was ≥ 97.9%; MDR Enterobacterales, 96.8%, 94.4% and 100%, respectively; DTR isolates, ≥ 76.2% to ceftazidime-avibactam and colistin; MEM-R, MBL-negative isolates, ≥ 90.0% to ceftazidime-avibactam and colistin.
- 650 _2
- $a antibakteriální látky $x farmakologie $x terapeutické užití $7 D000900
- 650 _2
- $a azabicyklické sloučeniny $7 D053961
- 650 _2
- $a ceftazidim $x farmakologie $7 D002442
- 650 12
- $a kolistin $x farmakologie $7 D003091
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a Enterobacteriaceae $7 D004755
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a meropenem $7 D000077731
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 12
- $a Pseudomonas aeruginosa $7 D011550
- 651 _2
- $a Chorvatsko $7 D017523
- 651 _2
- $a Česká republika $7 D018153
- 651 _2
- $a Maďarsko $7 D006814
- 651 _2
- $a Lotyšsko $7 D007844
- 651 _2
- $a Litva $7 D008097
- 651 _2
- $a Polsko $7 D011044
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mareković, I $u Department of Clinical and Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, Croatia
- 700 1_
- $a Szabó, J $u Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Pojnar, L $u Department of Microbiology, University Hospital, Cracow, Poland
- 700 1_
- $a Billová, S $u Pfizer, spol. s r.o., Prague, Czech Republic. sabina.billova@pfizer.com
- 700 1_
- $a Horvat Herceg, S $u Pfizer Croatia, Zagreb, Croatia
- 700 1_
- $a Kuraieva, A $u Pfizer Export B.V. RO, Kyiv, Ukraine
- 700 1_
- $a Możejko-Pastewka, B $u Pfizer Polska Sp. z o.o, Warsaw, Poland
- 773 0_
- $w MED00001612 $t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology $x 1435-4373 $g Roč. 41, č. 6 (2022), s. 989-996
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35596097 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134600 $b ABA008
- 999 __
- $a ok $b bmc $g 1821972 $s 1169400
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 41 $c 6 $d 989-996 $e 20220520 $i 1435-4373 $m European journal of clinical microbiology & infectious diseases $n Eur J Clin Microbiol Infect Dis $x MED00001612
- LZP __
- $a Pubmed-20220720
